Abstract
α-Synuclein is a major component of Lewy bodies in Parkinsons disease and is found associated with several other forms of dementia. As with other neurodegenerative diseases, the ability of α-synuclein to aggregate and form fibrillar deposits seems central to its pathology. We have defined a sequence within the NAC region of α-synuclein that is necessary for aggregation. Exploitation of chemically modified analogues of this peptide may produce inhibitors of aggregation.
Keywords: synuclein, amyloid, aggregation, parkinsons disease
Protein & Peptide Letters
Title: α-Synuclein Aggregation
Volume: 11 Issue: 3
Author(s): Angela M. Bodles and G. Brent Irvine
Affiliation:
Keywords: synuclein, amyloid, aggregation, parkinsons disease
Abstract: α-Synuclein is a major component of Lewy bodies in Parkinsons disease and is found associated with several other forms of dementia. As with other neurodegenerative diseases, the ability of α-synuclein to aggregate and form fibrillar deposits seems central to its pathology. We have defined a sequence within the NAC region of α-synuclein that is necessary for aggregation. Exploitation of chemically modified analogues of this peptide may produce inhibitors of aggregation.
Export Options
About this article
Cite this article as:
Bodles M. Angela and Irvine Brent G., α-Synuclein Aggregation, Protein & Peptide Letters 2004; 11 (3) . https://dx.doi.org/10.2174/0929866043407084
DOI https://dx.doi.org/10.2174/0929866043407084 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From the Editors Perspective: Inflammatory Glial Cells of the Nervous System: Assistants or Assassins?
Current Neurovascular Research Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Members:
Current Genomics Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers
Current Alzheimer Research Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology S-Nitrosylation and Attenuation of Excessive Calcium Flux by Pentacycloundecane Derivatives
Medicinal Chemistry Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Current Genomics Targeting Kinin Receptors for the Treatment of Neurological Diseases
Current Pharmaceutical Design Medicinal Chemistry of the Epigenetic Diet and Caloric Restriction
Current Medicinal Chemistry Novel Risk Factors Related to Stable Angina
Current Pharmaceutical Design Closure of Patent Foramen Ovale: When and How?
Current Vascular Pharmacology A Single Use Biosensor for the Detection of Nitric Oxide (NO) at ppb and sub-μM Level in Gas-and Liquid- Phase Media
Current Biomarkers (Discontinued) NGF-Cholinergic Dependency in Brain Aging, MCI and Alzheimers Disease
Current Alzheimer Research Neuro-Psychological Pattern in Patients Suffering from Primitive Dilated Cardiomyopathy with Impairment in Executive Function
Current Neurovascular Research Intracranial Cerebrospinal Fluid Volume Evaluation in Healthy People and Hydrocephalus Patients using SPACE Sequence
Current Medical Imaging Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?
CNS & Neurological Disorders - Drug Targets Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience